Company: JUNS
Filing Date: 2025-03-25
Form Type: 8-K
Source: 0001641172-25-000627
Chunk: 0

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-25
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On
March 21, 2025, Jupiter Neurosciences, Inc. (the “ Company”) received a letter (the “ Notice”) from the Nasdaq
Stock Market LLC (the “ NASDAQ”) notifying the Company that it is not in compliance with the minimum bid price requirement
as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing of its common stock on the NASDAQ.

Listing
Rule 5550(a)(2) requires the registrant to maintain a minimum bid price of $1.00 USD per share for its securities listed on the NASDAQ,
and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for
a period of 30 consecutive business days. Based on the closing bid price of the Company’s shares for the 30 consecutive business
days prior to the Notice (February 6, 2025 through March 20, 2025), the Company no longer meets the minimum bid price requirement.

However,
under NASDAQ Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until September 17, 2025, to regain compliance
with NASDAQ Listing Rule 5550(a)(2). During the 180-day period, the Company may regain compliance under Listing Rule 5550(a)(2) if the
bid price for the Company’s Common Stock is a least $1.00 USD for a minimum period of 10 consecutive days. In the event that the
Company does not regain compliance by September 17, 2025, the Company may be eligible for additional time to regain compliance or may
face delisting.

The
receipt of the Notification Letter has no immediate effect on the listing of the Company’s shares, which will continue to trade
uninterrupted on NASDAQ under the ticker “ JUNS”. The Company intends to monitor the closing price of its common stock sand
may, if appropriate, consider available options to regain compliance with the minimum bid price requirement. There can be no assurances
that the Company will be able to regain compliance with the minimum bid price requirement or maintain compliance with the other Nasdaq

Item
9.01 Financial Statements and Exhibits.